Document text
Principal Investigator: Robert Frederick Pagels
Organization: OPTIMEOS LIFE SCIENCES, INC.
Fiscal Year: 2022
Award: $287,726
Funding agency: National Center for Advancing Translational Sciences
Peptides can have exquisite potency and selectivity in treating disease, but suffer from rapid clearance.
Microparticle depot formulations, where the peptide is entrapped in a water-insoluble polymer matrix, have been
tested for decades to provide sustained therapeutic release for chronic disease. The traditional microparticle
structure has significant limitations, including low therapeutic content (<5 wt%) and inadequate release profiles.
Consequently, only 5 microparticle depots have been approved, representing 7% of marketed peptides. This
application seeks to develop a long-acting microparticle depot formulation using the inverse Flash
NanoPrecipitation (iFNP) platform being commercialized by Optimeos Life Sciences. iFNP enables the formation
of polymer-coated peptide-loaded nanoparticles in a scalable and continuous manner. These nanoparticles are
then clustered together to produce mechanically strong nanocomposite microparticles. The polymer coating
surrounding each individual nanoparticle allows for much higher peptide loadings and more controlled, sustained
release from the final microparticle.
The iFNP technology has been validated using a model peptide, liraglutide, with therapeutic efficacy
demonstrated in vivo for 1 month. The proposed research will apply the platform to three approved peptides that
currently lack long-acting formulations. The three peptides treat chronic disease and possess varying physical
properties. This proposed study will validate the universality of the platform and guide the selection of a lead
candidate for development:
1) Aim 1: Optimize encapsulation of three therapeutic peptide candidates in microparticle depots with
loadings above 30 wt%
2) Aim 2: Develop microparticle depots with sustained release profiles of active peptide over 1 month and
3 months with minimized peptide degradation.
The formulation design will build on the rules derived under an NSF STTR grant between Princeton University
and Optimeos. Peptides tested to date have all been chemically modified to increase circulation time. The
structure-encapsulation-release relationships identified in this work will advance our knowledge of suitable
candidates for formulation by the platform. Stability studies, using LC-MS analysis, will identify amino acid
residues with particular susceptibility to degradation that would be candidates for peptide modifications during
lead optimization of formulation candidates. Crucially, the proposed work will translate to the sustained delivery
of proteins, an application where no long-acting formulations are currently marketed.
Terms: <(Gly2)GLP-2><Address><Albumins><Amino Acids><Animal Model><Animal Models and Related Studies><Architecture><Beta Carotene><Betacarotene><Biologic Sciences><Biological Sciences><Bioscience><Blood Circulation><Bloodstream><Chemicals><Chronic><Chronic Disease><Chronic Illness><Circulation><Clinical Trials><Development><Diabetic mouse><Disease><Disorder><Dose><Emulsions><Encapsulated><Endocrine Gland Secretion><Engineering / Architecture><Enhancers><Exhibits><Formulation><Forteo><Frequencies><Funding><Future><Grant><Half-Life><Hormones><Hydrogen Oxide><Hydrophobicity><Hypoparathyroidism><Individual><Injectable><Injections><Knowledge><Lead><Legal patent><Life Sciences><Lipids><Mechanics><Messenger RNA><Methods><Modeling><Modification><Monitor><Obesity><Oral><Patents><Patients><Pb element><Peptide Hormone Gene><Peptide-based drug><Peptides><Performance><Phase><Polymers><Predisposition><Process><Production><Proteins><Research><SBIR><STTR><Schedule><Short Bowel Syndrome><Small Business Innovation Research><Small Business Innovation Research Grant><Small Business Technology Transfer Research><Solatene><Structure><Susceptibility><Technology><Teriparatide><Testing><Therapeutic><Therapeutic Effect><Therapeutic Hormone><Time><Translating><Treatment Efficacy><Universities><Water><Work><adiposity><aminoacid><beta,beta-Carotene><biodegradable polymer><biopharmaceutical company><biopharmaceutical industry><bioresorbable polymer><chemical stability><chronic disorder><clinical relevance><clinically relevant><commercialization><controlled release><corpulence><degradable polymer><design><designing><developmental><diabetes mouse model><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><hPTH (1-34)><heavy metal Pb><heavy metal lead><improved><in vivo><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><lead optimization><lipid based nanoparticle><lipid nanoparticle><liraglutide><mRNA><mechanical><model of animal><model organism><mouse model><murine model><nano composite><nano particle><nano-sized particle><nanocomposite><nanoparticle><nanosized particle><parenteral administration><parenteral delivery><parenteral infusion><peptide drug><peptide hormone><phase 2 study><phase II study><physical property><pre-clinical development><preclinical development><short gut syndrome><success><teduglutide><therapeutic efficacy><therapeutic peptide><therapy efficacy><β-Carotene>